5NQW image
Entry Detail
PDB ID:
5NQW
Keywords:
Title:
IgE-Fc in complex with single domain antibody 026
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2017-04-21
Release Date:
2018-01-17
Method Details:
Experimental Method:
Resolution:
3.40 Å
R-Value Free:
0.24
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Immunoglobulin heavy constant epsilon
Chain IDs:A, B
Chain Length:212
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:026
Chain IDs:C, D
Chain Length:134
Number of Molecules:2
Biological Source:Lama glama
Ligand Molecules
Primary Citation
Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts Fc epsilon RI interaction.
Nat Commun 9 7 7 (2018)
PMID: 29295972 DOI: 10.1038/s41467-017-02312-7

Abstact

Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. Here we report the crystal structure of an anti-IgE single-domain antibody in complex with an IgE Fc fragment, revealing how the antibody inhibits interactions between IgE and the two receptors FcεRI and CD23. The epitope overlaps only slightly with the FcεRI-binding site but significantly with the CD23-binding site. Solution scattering studies of the IgE Fc reveal that antibody binding induces a half-bent conformation in between the well-known bent and extended IgE Fc conformations. The antibody acts as functional homolog of CD23 and induces a closed conformation of IgE Fc incompatible with FcεRI binding. Notably the antibody displaces IgE from both CD23 and FcεRI, and abrogates allergen-mediated basophil activation and facilitated allergen binding. The inhibitory mechanism might facilitate strategies for the future development of anti-IgE therapeutics for treatment of allergic diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures